L-type cav 1.2 calcium channel-a-1C regulates response to rituximab in diffuse large B-cell lymphoma

Jiu Yang Zhang, Pei Pei Zhang, Wen Ping Zhou, Jia Yu Yu, Zhi Hua Yao, Jun Feng Chu, Shu Na Yao, Cheng Wang, Waseem Lone, Qing Xin Xia, Jie Ma, Shu Jun Yang, Kang Dong Liu, Zi Gang Dong, Yong Jun Guo, Lynette M. Smith, Timothy W. McKeithan, Wing C. Chan, Javeed Iqbal, Yan Yan Liu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: One third of patients with diffuse large B-cell lymphoma (DLBCL) succumb to the disease partly due to rituximab resistance. Rituximab-induced calcium flux is an important inducer of apoptotic cell death, and we investigated the potential role of calcium channels in rituximab resistance. Experimental Design: The distinctive expression of calcium channel members was compared between patients sensitive and resistant to rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone (RCHOP) regimen. The observation was further validated through mechanistic in vitro and in vivo studies using cell lines and patient-derived xenograft mouse models. Results: A significant inverse correlation was observed between CACNA1C expression and RCHOP resistance in two independent DLBCL cohorts, and CACNA1C expression was an independent prognostic factor for RCHOP resistance after adjusting for International Prognostic Index, cell-of-origin classification, and MYC/BCL2 double expression. Loss of CACNA1C expression reduced rituximab-induced apoptosis and tumor shrinkage. We further demonstrated direct interaction of CACNA1C with CD20 and its role in CD20 stabilization. Functional modulators of L-type calcium channel showed expected alteration in rituximab-induced apoptosis and tumor suppression. Furthermore, we demonstrated that CACNA1C expression was directly regulated by miR-363 whose high expression is associated with worse prognosis in DLBCL. Conclusions: We identified the role of CACNA1C in rituximab resistance, and modulating its expression or activity may alter rituximab sensitivity in DLBCL.

Original languageEnglish (US)
Pages (from-to)4168-4178
Number of pages11
JournalClinical Cancer Research
Volume25
Issue number13
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Calcium Channels
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Rituximab
Apoptosis
L-Type Calcium Channels
Helper-Inducer T-Lymphocytes
Heterografts
Neoplasms
Cell Death
Research Design
Observation
Calcium
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zhang, J. Y., Zhang, P. P., Zhou, W. P., Yu, J. Y., Yao, Z. H., Chu, J. F., ... Liu, Y. Y. (2019). L-type cav 1.2 calcium channel-a-1C regulates response to rituximab in diffuse large B-cell lymphoma. Clinical Cancer Research, 25(13), 4168-4178. https://doi.org/10.1158/1078-0432.CCR-18-2146

L-type cav 1.2 calcium channel-a-1C regulates response to rituximab in diffuse large B-cell lymphoma. / Zhang, Jiu Yang; Zhang, Pei Pei; Zhou, Wen Ping; Yu, Jia Yu; Yao, Zhi Hua; Chu, Jun Feng; Yao, Shu Na; Wang, Cheng; Lone, Waseem; Xia, Qing Xin; Ma, Jie; Yang, Shu Jun; Liu, Kang Dong; Dong, Zi Gang; Guo, Yong Jun; Smith, Lynette M.; McKeithan, Timothy W.; Chan, Wing C.; Iqbal, Javeed; Liu, Yan Yan.

In: Clinical Cancer Research, Vol. 25, No. 13, 01.01.2019, p. 4168-4178.

Research output: Contribution to journalArticle

Zhang, JY, Zhang, PP, Zhou, WP, Yu, JY, Yao, ZH, Chu, JF, Yao, SN, Wang, C, Lone, W, Xia, QX, Ma, J, Yang, SJ, Liu, KD, Dong, ZG, Guo, YJ, Smith, LM, McKeithan, TW, Chan, WC, Iqbal, J & Liu, YY 2019, 'L-type cav 1.2 calcium channel-a-1C regulates response to rituximab in diffuse large B-cell lymphoma', Clinical Cancer Research, vol. 25, no. 13, pp. 4168-4178. https://doi.org/10.1158/1078-0432.CCR-18-2146
Zhang, Jiu Yang ; Zhang, Pei Pei ; Zhou, Wen Ping ; Yu, Jia Yu ; Yao, Zhi Hua ; Chu, Jun Feng ; Yao, Shu Na ; Wang, Cheng ; Lone, Waseem ; Xia, Qing Xin ; Ma, Jie ; Yang, Shu Jun ; Liu, Kang Dong ; Dong, Zi Gang ; Guo, Yong Jun ; Smith, Lynette M. ; McKeithan, Timothy W. ; Chan, Wing C. ; Iqbal, Javeed ; Liu, Yan Yan. / L-type cav 1.2 calcium channel-a-1C regulates response to rituximab in diffuse large B-cell lymphoma. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 13. pp. 4168-4178.
@article{5e00b8005f804c688b6eb0c8876686ed,
title = "L-type cav 1.2 calcium channel-a-1C regulates response to rituximab in diffuse large B-cell lymphoma",
abstract = "Purpose: One third of patients with diffuse large B-cell lymphoma (DLBCL) succumb to the disease partly due to rituximab resistance. Rituximab-induced calcium flux is an important inducer of apoptotic cell death, and we investigated the potential role of calcium channels in rituximab resistance. Experimental Design: The distinctive expression of calcium channel members was compared between patients sensitive and resistant to rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone (RCHOP) regimen. The observation was further validated through mechanistic in vitro and in vivo studies using cell lines and patient-derived xenograft mouse models. Results: A significant inverse correlation was observed between CACNA1C expression and RCHOP resistance in two independent DLBCL cohorts, and CACNA1C expression was an independent prognostic factor for RCHOP resistance after adjusting for International Prognostic Index, cell-of-origin classification, and MYC/BCL2 double expression. Loss of CACNA1C expression reduced rituximab-induced apoptosis and tumor shrinkage. We further demonstrated direct interaction of CACNA1C with CD20 and its role in CD20 stabilization. Functional modulators of L-type calcium channel showed expected alteration in rituximab-induced apoptosis and tumor suppression. Furthermore, we demonstrated that CACNA1C expression was directly regulated by miR-363 whose high expression is associated with worse prognosis in DLBCL. Conclusions: We identified the role of CACNA1C in rituximab resistance, and modulating its expression or activity may alter rituximab sensitivity in DLBCL.",
author = "Zhang, {Jiu Yang} and Zhang, {Pei Pei} and Zhou, {Wen Ping} and Yu, {Jia Yu} and Yao, {Zhi Hua} and Chu, {Jun Feng} and Yao, {Shu Na} and Cheng Wang and Waseem Lone and Xia, {Qing Xin} and Jie Ma and Yang, {Shu Jun} and Liu, {Kang Dong} and Dong, {Zi Gang} and Guo, {Yong Jun} and Smith, {Lynette M.} and McKeithan, {Timothy W.} and Chan, {Wing C.} and Javeed Iqbal and Liu, {Yan Yan}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-18-2146",
language = "English (US)",
volume = "25",
pages = "4168--4178",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - L-type cav 1.2 calcium channel-a-1C regulates response to rituximab in diffuse large B-cell lymphoma

AU - Zhang, Jiu Yang

AU - Zhang, Pei Pei

AU - Zhou, Wen Ping

AU - Yu, Jia Yu

AU - Yao, Zhi Hua

AU - Chu, Jun Feng

AU - Yao, Shu Na

AU - Wang, Cheng

AU - Lone, Waseem

AU - Xia, Qing Xin

AU - Ma, Jie

AU - Yang, Shu Jun

AU - Liu, Kang Dong

AU - Dong, Zi Gang

AU - Guo, Yong Jun

AU - Smith, Lynette M.

AU - McKeithan, Timothy W.

AU - Chan, Wing C.

AU - Iqbal, Javeed

AU - Liu, Yan Yan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: One third of patients with diffuse large B-cell lymphoma (DLBCL) succumb to the disease partly due to rituximab resistance. Rituximab-induced calcium flux is an important inducer of apoptotic cell death, and we investigated the potential role of calcium channels in rituximab resistance. Experimental Design: The distinctive expression of calcium channel members was compared between patients sensitive and resistant to rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone (RCHOP) regimen. The observation was further validated through mechanistic in vitro and in vivo studies using cell lines and patient-derived xenograft mouse models. Results: A significant inverse correlation was observed between CACNA1C expression and RCHOP resistance in two independent DLBCL cohorts, and CACNA1C expression was an independent prognostic factor for RCHOP resistance after adjusting for International Prognostic Index, cell-of-origin classification, and MYC/BCL2 double expression. Loss of CACNA1C expression reduced rituximab-induced apoptosis and tumor shrinkage. We further demonstrated direct interaction of CACNA1C with CD20 and its role in CD20 stabilization. Functional modulators of L-type calcium channel showed expected alteration in rituximab-induced apoptosis and tumor suppression. Furthermore, we demonstrated that CACNA1C expression was directly regulated by miR-363 whose high expression is associated with worse prognosis in DLBCL. Conclusions: We identified the role of CACNA1C in rituximab resistance, and modulating its expression or activity may alter rituximab sensitivity in DLBCL.

AB - Purpose: One third of patients with diffuse large B-cell lymphoma (DLBCL) succumb to the disease partly due to rituximab resistance. Rituximab-induced calcium flux is an important inducer of apoptotic cell death, and we investigated the potential role of calcium channels in rituximab resistance. Experimental Design: The distinctive expression of calcium channel members was compared between patients sensitive and resistant to rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone (RCHOP) regimen. The observation was further validated through mechanistic in vitro and in vivo studies using cell lines and patient-derived xenograft mouse models. Results: A significant inverse correlation was observed between CACNA1C expression and RCHOP resistance in two independent DLBCL cohorts, and CACNA1C expression was an independent prognostic factor for RCHOP resistance after adjusting for International Prognostic Index, cell-of-origin classification, and MYC/BCL2 double expression. Loss of CACNA1C expression reduced rituximab-induced apoptosis and tumor shrinkage. We further demonstrated direct interaction of CACNA1C with CD20 and its role in CD20 stabilization. Functional modulators of L-type calcium channel showed expected alteration in rituximab-induced apoptosis and tumor suppression. Furthermore, we demonstrated that CACNA1C expression was directly regulated by miR-363 whose high expression is associated with worse prognosis in DLBCL. Conclusions: We identified the role of CACNA1C in rituximab resistance, and modulating its expression or activity may alter rituximab sensitivity in DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=85068524442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068524442&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-2146

DO - 10.1158/1078-0432.CCR-18-2146

M3 - Article

C2 - 30824586

AN - SCOPUS:85068524442

VL - 25

SP - 4168

EP - 4178

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -